A Phase 1/2 Study of Flavocoxid, an Oral NF-κB Inhibitor, in Duchenne Muscular Dystrophy
Vita, G.L.; Sframeli, M.; Licata, N.; Bitto, A.; Romeo, S.; Frisone, F.; Ciranni, A.; Pallio, G.; Mannino, F.; Aguennouz, M.; Rodolico, C.; Squadrito, F.; Toscano, A.; Messina, S.; Vita, G. A Phase 1/2 Study of Flavocoxid, an Oral NF-κB Inhibitor, in Duchenne Muscular Dystrophy. Brain Sci. 2021, 11, 115. https://doi.org/10.3390/brainsci11010115
Vita GL, Sframeli M, Licata N, Bitto A, Romeo S, Frisone F, Ciranni A, Pallio G, Mannino F, Aguennouz M, Rodolico C, Squadrito F, Toscano A, Messina S, Vita G. A Phase 1/2 Study of Flavocoxid, an Oral NF-κB Inhibitor, in Duchenne Muscular Dystrophy. Brain Sciences. 2021; 11(1):115. https://doi.org/10.3390/brainsci11010115
Chicago/Turabian StyleVita, Gian L., Maria Sframeli, Norma Licata, Alessandra Bitto, Sara Romeo, Francesca Frisone, Annamaria Ciranni, Giovanni Pallio, Federica Mannino, M’Hammed Aguennouz, Carmelo Rodolico, Francesco Squadrito, Antonio Toscano, Sonia Messina, and Giuseppe Vita. 2021. "A Phase 1/2 Study of Flavocoxid, an Oral NF-κB Inhibitor, in Duchenne Muscular Dystrophy" Brain Sciences 11, no. 1: 115. https://doi.org/10.3390/brainsci11010115